crwepicks'  Instablog

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.

Power3 Medical Products, Inc ., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced recently that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease in Honolulu, Hawaii. These presentations discussed NuroPro, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

Alzheimer’s disease is a progressive and fatal brain disease. Alzheimer’s destroys brain cells, causing memory loss and problems with thinking and behavior severe enough to affect work, lifelong hobbies or social life. Alzheimer’s gets worse over time, and it is fatal. Today it is the seventh-leading cause of death in the United States.

Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

Power3 Medical Products, Inc., a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. The company was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. Power3 Medical Products, Inc . was founded in 1992 and is based in The Woodlands, Texas.

To learn more about PWRM visit: www.Power3Medical.com

 

 

 

Maui Land & Pineapple Company, Inc. (NYSE:MLP) recently reported net income of $20.0 million, or $1.35 per share, for the third quarter of 2010, compared to a net loss of $25.5 million, or ($3.17) per share, for the third quarter of 2009.

Revenues for the third quarter of 2010 were $8.2 million, compared to $20.1 million for the third quarter of 2009.

 

Jones Soda Co. (NASDAQ:JSDA), a leader in the premium soda category and known for its unique branding and innovative marketing, will host a conference call to discuss financial results for its third quarter ended September 30, 2010, on Thursday, November 11, 2010, at 4:30 p.m. Eastern Time.

JSDA will announce its financial results for this period in a press release after the market close on November 11, 2010.

 

Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) recently reported that it has filed its Form 10-Q with the Securities and Exchange Commission.

APP Pharmaceuticals, Inc., which was acquired by APCVZ, is a member of the Fresenius Kabi Group. The Form 10-Q details the Company’s unaudited financial statements for the quarter ending September 30, 2010.

 

 

*******************************************
Sign-Up For Free Stock Alerts At crwepicks.com/signup
*******************************************


THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).